Q-omics provides the consensus-scored SNORD38C profile across patient tissues and cancer cell-line models. SNORD38C expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SNORD38C is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, SNORD38C RNA expression shows 5,851 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, LUAD, and STAD as cancer lineages where SNORD38C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD38C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD38C survival associations across molecular data types. SNORD38C RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD38C RNA expression–survival associations across cancer types. High SNORD38C expression shows unfavorable associations in CESC, ACC, DLBC, MESO, UCEC and TGCT. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify CESC as the clearest survival context for SNORD38C RNA expression.
This table summarizes SNORD38C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD38C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD38C shows lower tumor expression in LUAD and LUSC. The LUAD box plot shows higher SNORD38C RNA expression in normal versus tumor tissue (log2 FC = −0.533, t-test p = .025).
This table shows molecular features associated with SNORD38C in patient tissues and cancer cell lines. In patient samples, SNORD38C shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
